文献リスト

1）Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002; 346: 995-1008

2）柏木浩和．ITPの病態解析．In: 高久史麿，他編. Annual Review 血液　2014. 東京. 中外医学社; 2014. p.192-7

3）McMillan R, Wang L, Tomer A, et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004; 103: 1364-9

4）Rodegheiro F, Stasi R, Gernsheimer T, et al. Standarization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009; 113: 2386-93

5）蔵本　淳．特発性血小板減少性紫斑病分科会報告. In: 厚労省特定疾患「特発性造血障害」調査研究班平成2年度研究業績報告書. 1991. p.59-63

6）Geroge JN, Woolf SH, Wasser JS, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the Am-erican Society Hematology. Blood. 1996; 88: 3-40

7）British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003; 120: 574-96

8）藤村欣吾．免疫性血小板減少性紫斑病（ＩＴＰ）における治療ガイドライン（案）の提案―ヘリコバクター・ピロリ菌除菌療法の成績を踏まえて. 厚生労働科学研究補助金. 難治性疾患克服研究事業　血液凝固異常症に関する調査研究　平成16年度報告書. 2004. p.53-69

9）Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115: 168-86

10）Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practical guideline for immune thrombocytopenia. Blood. 2011; 117: 4190-207

11）藤村欣吾，宮川義隆，倉田義之，他．成人特発性血小板減少性紫斑病治療の参照ガイド2012年版．臨床血液．2012; 53: 433-42

12）Lee LH, Caguioa P, Chin NS, et al. Chronic adult primary immune thrombocytopenia (ITP) in the Asia-Pacific region. Int J Hematol. 2011; 94: 142-9

13）日本小児血液学会ITP委員会. 白幡　聡，石井栄一，江口春彦，他. 小児特発性血小板減少性紫斑病―診断・治療・管理ガイドラインー. 日小血会誌. 2004; 18: 210-8

14）Nawata H, Soen S, Takayanagi R, et al. Guidelines on the management and treatment of glucocorticoid- induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab. 2005; 23: 105-9

15）Sakamoto K, Nakasone H, Tsurumi S, et al. Prednisone versus high-dose dexamethasone for untreated primary immune thrombocytopenia. A retrospective study of the Japan Hematology & Oncology Clinical Study Group. J Thromb Thrombolysis. 2014; 37: 279-86

16）Gudbrandsdottir S, Birgens HS, Frederiksen H, et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood. 2013; 121: 1976-81

17）Gómez-Almaguer D, Tarín-Arzaga L, Moreno-Jaime B, et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2013; 90: 494-500

18）Gómez-Almaguer D, Herrera-Rojas MA, Jaime-Pérez JC, et al. Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. Blood. 2014; 123: 3906-8

19）Choi PY, Roncolato F, Badoux X, et al. A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). Blood. 2015; 126: 500-3

20）Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001; 98: 3241-8

21）Shirasugi Y, Ando K, Miyazaki K, et al. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial. Int J Hematol. 2011; 94: 71-80

22）Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008; 371: 395-403

23）Tomiyama Y, Miyakawa Y, Okamoto S, et al. A lower starting dose of eltrombopag is efficacious in Japnese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost. 2012; 10: 799-806

24）Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomized, double-blind, placebo-controllled trial. Lancet. 2009; 373: 641-8

25）George JN, Mathias SD, Go RS, et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol. 2009; 144: 409-15

26）Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011; 377: 393-402

27）Shirasugi Y, Ando K, Miyazaki K, et al. An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3. 5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP). Int J Hematol. 2012; 95: 652-9

28）Kuter DJ, Bussel JB, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013; 161: 411-23

29）Katsutani S, Tomiyama Y, Kimura A, et al. Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study. Int J Hematol. 2013; 98: 323-30

30）Saleh MN, Bussel JB, Cheng G, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013; 121: 537-45

31）Khellaf M, Viallard JF, Hamidou M, et al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica. 2013; 98: 881-7

32）González-López TJ, Pascual C, Álvarez-Román MT, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol. 2015; 90: E40-3

33）Mahévas M, Fain O, Ebbo M, et al. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol. 2014; 165: 865-9

34）Červinek L1, Mayer J, Doubek M. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults. Int J Hematol. 2015; 102: 7-11

35）Bao W, Bussel JB, Heck S, et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood. 2010; 116: 4639-45

36）Ruggeri M, Tosetto A, Palandri F, et al. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. J Thromb Haemost. 2014; 12: 1266-73

37）Boyle S, White RH, Brunson A, et al. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood 2013; 121: 4782-90

38）Amold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Int Med. 2007; 146: 25-33

39）Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012; 119: 5989-95

40）Zaja F, Volpetti S, Chiozzotto M, et al. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia. Am J Hematol. 2012; 87: 886-9

41）Khellaf M, Charles-Nelson A, Fain O, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014; 124: 3228-36

42）Miyakawa Y, Katsutani S, Yano T, et al. Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy. Int J Hematol. 2015 Oct 14. [Epub ahead of print]

43）Ghanima W, Khelif A, Waage A, et al. RITP study group. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicenter, randomized, double-blind, placebo-controlled trial. Lancet. 2015; 385: 1653-61

44）Nazi I, Kelton JG, Larché M, et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood. 2013; 122: 1946-53

45）宮川義隆，柏木浩和，高蓋寿朗，他. 妊娠合併特発性血小板減少性紫斑病診療の参照ガイド. 臨床血液. 2014; 55: 433-42

46）Fujimura K, Harada Y, Fujimoto T, et al. Nationwide study of idiopathic thrombocytopenic purpura in pregnant women and the clinical influence on neonates. Int J Hematol. 2002; 75: 426-33

47）van Veen JJ, Nokes TJ, Makris M. The risk of spinal haematoma following neuraxial　anaesthesia or lumbar puncture in thrombocytopenic individuals. Br J Haematol. 2009; 148: 15-25

48）Gernsheimer T, James AH, Stasi R. How I treat thrombocytopenia in pregnancy. Blood. 2013; 121: 38-47

49）Gill KK, Kelton JG. Management of idiopathic thrombocytopenic purpura in pregnancy. Sem Hematol. 2000; 37: 275-89

50）Kadir RA, McLintock C. Thrombocytopenia and disorders of platelet function in pregnancy. Semin Thromb Hemost. 2011; 37: 640-52

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp